Viehbacher, "Biogen") announced today that the humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody "LEQEMBI®" has been launched in South Korea. LEQEMBI received the Ministry of ...

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...

Cambridge, Massachusetts-based Biogen Inc. ( BIIB) discovers, develops, manufactures, and delivers therapies for treating ...

Begin your TipRanks Premium journey today. Biogen (BIIB) Company Description: Incorporated in 1978, Massachusetts-based Biogen, Inc. is a biopharmaceutical company, which discovers, develops, and ...

A third trial failure this year for the same experimental neurological drug has led Sage Therapeutics to discontinue ...

A European regulatory committee now recommends approval of the Alzheimer's treatment lecanemab a few months after rejecting ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts ...

Biogen, headquartered in Cambridge, Massachusetts, has established itself as a key player in the biopharmaceutical industry, focusing on innovative therapies for neurological conditions.

Co-developed with Biogen Inc. (Nasdaq ... that it was laying off more than 165 employees — 69 of whom work in Massachusetts — or about 33% of the company’s total workforce.

We’ve debated immigration since Native Americans encountered a group of migrants from England who decided to settle in ...